Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
Conditions
Interventions
Intervention1: Dapagliflozin: Dapagliflozin will be given once daily 10mg for 12 weeks as add on therapy in elderly uncontrolled type 2 diabetes mellitus patients
Control Intervention1: Sitagliptin: S
Sponsors
Dr Mukku Venkata Pratap Reddy
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients with type 2 diabetes who are taking Metformin in combination with Sulfonylurea and target levels not achieved according to ADA Guidelines 2)Patients age greater than or equal to 60 years of either sex and who are willing to participate in study
Exclusion criteria
Exclusion criteria: e GFR less than 20 ml/min/1.73 m2, CKD patient on maintenance hemodialysis. 2)Type 2 Diabetes Patients PLHA. 3)Patients with hemoglobinopathies, Severe Anemia Hb 4)Patients already taking DPP4 inhibitors, SGLT2 inhibitors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate and compare the change in HbA1c values from baseline at 12 weeks in both the groupsTimepoint: 3months | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the incidence of all major adverse events during 12 weeks of therapy To compare effect on renal outcome in both groups after 12 weeks of therapy To compare effect on lipid profile in both the groups after 12 weeks of therapy Timepoint: 3months | — |
Countries
India
Contacts
Public ContactDr Mukku Venkata Pratap Reddy
All India Institute of Medical Sciences Bhubaneswar
Outcome results
None listed